Tussilagone ameliorates high‐fat diet‐induced hepatic steatosis by enhancing energy metabolism and antioxidant activity
Phytotherapy Research · 2024
DOI: 10.1002/ptr.7818 ↗At a glance
Journal article in Phytotherapy Research, 2024. Written by Mingjie Sun and 12 co-authors. Institution: College of Animal Science and Technology, Guangxi University, Nanning, 530004, China. Major MEDLINE topics: Diet, High-Fat, Non-alcoholic Fatty Liver Disease, Antioxidants, Energy Metabolism. Cited 9 times so far (Crossref); 59 references. Funded by: Guangxi Health Commission Key Laboratory of Portal Hypertension Prevention and Control Research, Guangxi Digestive Disease Clinical Medical Research Center Construction Project, Guangxi Natural Science Foundation.
Abstract (original language)
Non‐alcoholic fatty liver disease (NAFLD) is a major health problem. However, no effective treatments are currently available. Thus, there is a critical need to develop novel drugs that can prevent and treat NAFLD with few side effects. In this study, Tussilagone (TUS), a natural sesquiterpene isolated from Tussilago farfara L , was explored in vitro and in vivo for its potential to treat NAFLD. Our results showed that in vitro TUS reduced oleic acid palmitate acid‐induced triglyceride and cholesterol synthesis in HepG 2 cells, reduced intracellular lipid droplet accumulation, improved glucose metabolism disorders and increased energy metabolism and reduced oxidative stress levels. In vivo, TUS significantly reduced fat accumulation and improved liver injury in high‐fat diet (HFD)‐induced mice. TUS treatment significantly increased liver mitochondrial counts and antioxidant levels compared to the HFD group of mice. In addition, TUS was found to reduce the expression of genes involved in lipid synthesis sterol regulatory element binding protein‐1 (SREBP1), fatty acid synthase (FASN), and stearoy‐CoA desaturase 1 (SCD1) in vitro and in vivo. Our results suggest that TUS may be helpful in the treatment of NAFLD, suggesting that TUS is a promising compound for the treatment of NAFLD. Our findings provided novel insights into the application of TUS in regulating lipid metabolism.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Animal Science and Technology, Guangxi University, Nanning, 530004, China.
- Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530021, China.
Funding
- Guangxi Health Commission Key Laboratory of Portal Hypertension Prevention and Control Research
- Guangxi Digestive Disease Clinical Medical Research Center Construction Project
- Guangxi Natural Science Foundation
- Guangxi Science Foundation for Distinguished Young Scholars
- National Natural Science Foundation of China
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
Cite
APA
Sun, M., Li, Y., Su, S., Gao, J., Yu, L., Qi, X., Liang, H., Li, X., Qi, X., Liang, Y., Zhou, L., Zhang, G., & Li, Y. (2024). Tussilagone ameliorates high‐fat diet‐induced hepatic steatosis by enhancing energy metabolism and antioxidant activity. Phytotherapy Research. https://doi.org/10.1002/ptr.7818
Vancouver
Sun M, Li Y, Su S, Gao J, Yu L, Qi X, et al. Tussilagone ameliorates high‐fat diet‐induced hepatic steatosis by enhancing energy metabolism and antioxidant activity. Phytotherapy Research. 2024. doi:10.1002/ptr.7818
BibTeX
@article{Sun2024,
author = {Sun, Mingjie and Li, Yu and Su, Songtao and Gao, Jiayi and Yu, Lin and Qi, Xinyi and Liang, Huanjie and Li, Xiangling and Qi, Xinyu and Liang, Yunxiao and Zhou, Lei and Zhang, Guo and Li, Yixing},
title = {Tussilagone ameliorates high‐fat diet‐induced hepatic steatosis by enhancing energy metabolism and antioxidant activity},
journal = {Phytotherapy Research},
year = {2024},
doi = {10.1002/ptr.7818}
}
EUVIMED